Aurinia Pharmaceuticals (AUPH) Stock Forecast, Price Target & Predictions
AUPH Stock Forecast
Aurinia Pharmaceuticals stock forecast is as follows: an average price target of $13.00 (represents a 45.25% upside from AUPH’s last price of $8.95) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
AUPH Price Target
AUPH Analyst Ratings
Buy
Aurinia Pharmaceuticals Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Sep 06, 2024 | Ed Arce | H.C. Wainwright | $13.00 | $6.91 | 88.13% | 45.25% |
May 02, 2024 | Maury Raycroft | Jefferies | $6.00 | $5.10 | 17.65% | -32.96% |
Jan 04, 2023 | RBC Capital | $11.00 | $5.94 | 85.19% | 22.91% | |
Aug 09, 2022 | H.C. Wainwright | $26.00 | $8.27 | 214.39% | 190.50% | |
Aug 08, 2022 | Oppenheimer | $13.00 | $8.37 | 55.32% | 45.25% | |
May 05, 2022 | H.C. Wainwright | $30.00 | $11.37 | 163.85% | 235.20% | |
Apr 28, 2022 | RBC Capital | $22.00 | $10.41 | 111.34% | 145.81% |
Aurinia Pharmaceuticals Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 2 |
Avg Price Target | - | - | $9.50 |
Last Closing Price | $8.95 | $8.95 | $8.95 |
Upside/Downside | -100.00% | -100.00% | 6.15% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
May 02, 2024 | Jefferies | Hold | Hold | Hold |
Jan 04, 2023 | RBC Capital | Outperform | Outperform | Hold |
Aug 08, 2022 | Oppenheimer | Outperform | Outperform | Hold |
Apr 28, 2022 | RBC Capital | Outperform | Outperform | Hold |
Feb 23, 2022 | RBC Capital | Outperform | Outperform | Hold |
Dec 10, 2021 | Oppenheimer | Outperform | Upgrade |
Aurinia Pharmaceuticals Financial Forecast
Aurinia Pharmaceuticals Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $42.31M | $40.78M | $41.49M | $34.41M | $28.43M | $55.78M | $28.19M | $21.63M | $23.40M | $14.67M | $6.62M | $914.00K | $50.03M | $29.00K | $29.00K | $30.00K | $29.00K | $230.00K | $29.00K | $30.00K | $30.00K | $31.00K |
Avg Forecast | $69.20M | $66.55M | $66.55M | $62.55M | $60.11M | $57.48M | $54.25M | $47.07M | $45.00M | $38.44M | $37.90M | $27.87M | $27.77M | $36.19M | $27.04M | $19.23M | $22.00M | $13.87M | $4.96M | $3.03M | $12.53M | $43.43K | $27.56K | $37.00K | $61.71K | $41.50K | $44.00K | $38.00K | $28.33K | $3.91K |
High Forecast | $71.64M | $68.90M | $68.90M | $64.64M | $68.35M | $58.17M | $54.25M | $47.07M | $46.59M | $39.94M | $39.23M | $28.86M | $28.75M | $36.19M | $27.04M | $19.23M | $22.00M | $13.87M | $4.96M | $3.03M | $12.53M | $43.43K | $27.56K | $37.00K | $61.71K | $41.50K | $44.00K | $38.00K | $34.00K | $4.69K |
Low Forecast | $66.56M | $64.01M | $64.01M | $60.46M | $55.47M | $56.79M | $54.25M | $47.07M | $42.54M | $36.44M | $36.45M | $26.81M | $26.71M | $36.19M | $27.04M | $19.23M | $22.00M | $13.87M | $4.96M | $3.03M | $12.53M | $43.43K | $27.56K | $37.00K | $61.71K | $41.50K | $44.00K | $38.00K | $22.66K | $3.13K |
# Analysts | 1 | 1 | 1 | 2 | 5 | 4 | 1 | 1 | 3 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 18 |
Surprise % | - | - | - | - | - | - | - | - | 0.94% | 1.06% | 1.09% | 1.23% | 1.02% | 1.54% | 1.04% | 1.12% | 1.06% | 1.06% | 1.33% | 0.30% | 3.99% | 0.67% | 1.05% | 0.81% | 0.47% | 5.54% | 0.66% | 0.79% | 1.06% | 7.92% |
Forecast
Aurinia Pharmaceuticals EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 5 | 4 | 1 | 1 | 3 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 18 |
EBITDA | - | - | - | - | - | - | - | - | $-29.67M | $-16.26M | $-11.35M | $-29.58M | $-28.10M | $-8.69M | $-35.15M | $-37.04M | $-31.80M | $-49.46M | $-46.15M | $-49.51M | $-22.09M | $-33.50M | $-28.93M | $-16.34M | $-75.99M | $-18.61M | $-15.38M | $-12.02M | $-14.84M | $-51.50M |
Avg Forecast | $-57.19M | $-55.00M | $-55.00M | $-51.70M | $-49.68M | $-47.51M | $-44.84M | $-44.19M | $-37.19M | $-31.77M | $-31.32M | $-40.17M | $-32.04M | $-30.69M | $-22.93M | $-36.52M | $-18.65M | $-11.76M | $-4.21M | $-44.16M | $-10.63M | $-36.83K | $-23.37K | $-21.24M | $-52.33K | $-35.19K | $-37.31K | $-12.82M | $-14.19M | $-263.05M |
High Forecast | $-55.01M | $-52.90M | $-52.90M | $-49.97M | $-45.85M | $-46.94M | $-44.84M | $-35.35M | $-35.16M | $-30.12M | $-30.13M | $-32.14M | $-25.64M | $-30.69M | $-22.93M | $-29.22M | $-18.65M | $-11.76M | $-4.21M | $-35.33M | $-10.63M | $-36.83K | $-23.37K | $-17.00M | $-52.33K | $-35.19K | $-37.31K | $-10.26M | $-11.35M | $-210.44M |
Low Forecast | $-59.21M | $-56.94M | $-56.94M | $-53.43M | $-56.49M | $-48.08M | $-44.84M | $-53.03M | $-38.51M | $-33.01M | $-32.43M | $-48.21M | $-38.45M | $-30.69M | $-22.93M | $-43.82M | $-18.65M | $-11.76M | $-4.21M | $-53.00M | $-10.63M | $-36.83K | $-23.37K | $-25.49M | $-52.33K | $-35.19K | $-37.31K | $-15.39M | $-17.03M | $-315.66M |
Surprise % | - | - | - | - | - | - | - | - | 0.80% | 0.51% | 0.36% | 0.74% | 0.88% | 0.28% | 1.53% | 1.01% | 1.70% | 4.21% | 10.97% | 1.12% | 2.08% | 909.55% | 1238.20% | 0.77% | 1452.05% | 528.94% | 412.13% | 0.94% | 1.05% | 0.20% |
Forecast
Aurinia Pharmaceuticals Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 5 | 4 | 1 | 1 | 3 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 18 |
Net Income | - | - | - | - | - | - | - | - | $-26.88M | $-13.45M | $-11.49M | $-26.21M | $-26.05M | $-8.99M | $-35.52M | $-37.63M | $-33.32M | $-50.26M | $-47.01M | $-50.38M | $-22.56M | $-34.06M | $-29.53M | $-16.53M | $-76.48M | $-19.04M | $-15.90M | $-12.43M | $-15.48M | $-51.94M |
Avg Forecast | $21.85M | $18.21M | $17.48M | $15.29M | $2.33M | $2.18M | $1.21M | $-45.53M | $-23.79M | $-24.34M | $-26.70M | $-41.39M | $-33.46M | $-33.43M | $-31.91M | $-37.63M | $-38.70M | $-47.97M | $-52.60M | $-44.78M | $-28.46M | $-33.56M | $-33.31M | $-21.49M | $-29.03M | $-27.14M | $-22.77M | $-13.26M | $-14.57M | $-264.90M |
High Forecast | $22.85M | $19.04M | $18.28M | $15.99M | $5.33M | $2.28M | $1.24M | $-36.43M | $-18.50M | $-18.62M | $-25.38M | $-33.11M | $-26.77M | $-33.43M | $-31.91M | $-30.10M | $-38.70M | $-47.97M | $-52.60M | $-35.83M | $-28.46M | $-33.56M | $-33.31M | $-17.20M | $-29.03M | $-27.14M | $-22.77M | $-10.61M | $-11.65M | $-211.92M |
Low Forecast | $20.76M | $17.30M | $16.61M | $13.90M | $-2.00M | $2.08M | $1.19M | $-54.64M | $-31.72M | $-27.21M | $-27.93M | $-49.67M | $-40.16M | $-33.43M | $-31.91M | $-45.16M | $-38.70M | $-47.97M | $-52.60M | $-53.74M | $-28.46M | $-33.56M | $-33.31M | $-25.79M | $-29.03M | $-27.14M | $-22.77M | $-15.91M | $-17.48M | $-317.88M |
Surprise % | - | - | - | - | - | - | - | - | 1.13% | 0.55% | 0.43% | 0.63% | 0.78% | 0.27% | 1.11% | 1.00% | 0.86% | 1.05% | 0.89% | 1.13% | 0.79% | 1.02% | 0.89% | 0.77% | 2.63% | 0.70% | 0.70% | 0.94% | 1.06% | 0.20% |
Forecast
Aurinia Pharmaceuticals SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 5 | 4 | 1 | 1 | 3 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 18 |
SG&A | - | - | - | - | - | - | - | - | $50.07M | $47.76M | $47.08M | $50.12M | $47.47M | $52.17M | $51.53M | $45.20M | $44.24M | $44.13M | $43.79M | $39.28M | $38.31M | $31.07M | $15.54M | $11.06M | $7.25M | $6.06M | $4.95M | $3.90M | $3.79M | $3.43M |
Avg Forecast | $1.08B | $1.04B | $1.04B | $974.75M | $936.74M | $895.75M | $845.44M | $733.58M | $701.26M | $599.00M | $590.57M | $434.38M | $432.81M | $563.90M | $421.42M | $299.68M | $342.76M | $216.13M | $77.30M | $47.19M | $195.34M | $676.77K | $429.42K | $576.59K | $961.72K | $646.71K | $685.67K | $592.17K | $441.53K | $60.98K |
High Forecast | $1.12B | $1.07B | $1.07B | $1.01B | $1.07B | $906.54M | $845.45M | $733.59M | $726.05M | $622.34M | $611.39M | $449.70M | $448.07M | $563.90M | $421.42M | $299.68M | $342.76M | $216.13M | $77.30M | $47.19M | $195.34M | $676.77K | $429.42K | $576.59K | $961.72K | $646.71K | $685.67K | $592.17K | $529.81K | $73.15K |
Low Forecast | $1.04B | $997.49M | $997.49M | $942.16M | $864.44M | $884.95M | $845.44M | $733.58M | $662.94M | $567.89M | $568.03M | $417.80M | $416.28M | $563.90M | $421.42M | $299.68M | $342.76M | $216.13M | $77.30M | $47.19M | $195.34M | $676.77K | $429.42K | $576.59K | $961.72K | $646.71K | $685.67K | $592.17K | $353.20K | $48.76K |
Surprise % | - | - | - | - | - | - | - | - | 0.07% | 0.08% | 0.08% | 0.12% | 0.11% | 0.09% | 0.12% | 0.15% | 0.13% | 0.20% | 0.57% | 0.83% | 0.20% | 45.91% | 36.19% | 19.18% | 7.53% | 9.37% | 7.21% | 6.59% | 8.59% | 56.20% |
Forecast
Aurinia Pharmaceuticals EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 5 | 4 | 1 | 1 | 3 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 18 |
EPS | - | - | - | - | - | - | - | - | $-0.19 | $-0.09 | $-0.08 | $-0.18 | $-0.18 | $-0.06 | $-0.25 | $-0.27 | $-0.25 | $-0.39 | $-0.37 | $-0.40 | $-0.05 | $-0.28 | $-0.26 | $-0.15 | $-0.78 | $-0.21 | $-0.17 | $-0.14 | $-0.18 | $-0.92 |
Avg Forecast | $0.15 | $0.13 | $0.12 | $0.10 | $0.02 | $0.01 | $0.01 | $-0.14 | $-0.16 | $-0.17 | $-0.18 | $-0.22 | $-0.27 | $-0.23 | $-0.22 | $-0.27 | $-0.27 | $-0.33 | $-0.36 | $-0.37 | $-0.20 | $-0.23 | $-0.23 | $-0.19 | $-0.20 | $-0.19 | $-0.16 | $-0.15 | $-0.16 | $-0.61 |
High Forecast | $0.16 | $0.13 | $0.13 | $0.11 | $0.04 | $0.02 | $0.01 | $-0.13 | $-0.13 | $-0.13 | $-0.17 | $-0.21 | $-0.26 | $-0.23 | $-0.22 | $-0.27 | $-0.27 | $-0.33 | $-0.36 | $-0.37 | $-0.20 | $-0.23 | $-0.23 | $-0.19 | $-0.20 | $-0.19 | $-0.16 | $-0.15 | $-0.13 | $-0.49 |
Low Forecast | $0.14 | $0.12 | $0.11 | $0.10 | $-0.01 | $0.01 | $0.01 | $-0.14 | $-0.22 | $-0.19 | $-0.19 | $-0.23 | $-0.28 | $-0.23 | $-0.22 | $-0.27 | $-0.27 | $-0.33 | $-0.36 | $-0.37 | $-0.20 | $-0.23 | $-0.23 | $-0.19 | $-0.20 | $-0.19 | $-0.16 | $-0.15 | $-0.19 | $-0.73 |
Surprise % | - | - | - | - | - | - | - | - | 1.16% | 0.56% | 0.44% | 0.81% | 0.67% | 0.27% | 1.13% | 1.01% | 0.93% | 1.17% | 1.01% | 1.08% | 0.25% | 1.20% | 1.13% | 0.78% | 3.87% | 1.12% | 1.08% | 0.96% | 1.13% | 1.51% |
Forecast
Aurinia Pharmaceuticals Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
HEPA | Hepion Pharmaceuticals | $0.52 | $70.00 | 13361.54% | Buy |
TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
BTAI | BioXcel Therapeutics | $0.39 | $1.00 | 156.41% | Buy |
VKTX | Viking Therapeutics | $46.70 | $97.80 | 109.42% | Buy |
AKRO | Akero Therapeutics | $30.61 | $50.00 | 63.35% | Buy |
SRPT | Sarepta Therapeutics | $125.76 | $187.20 | 48.85% | Buy |
AXSM | Axsome Therapeutics | $93.51 | $133.00 | 42.23% | Buy |
MCRB | Seres Therapeutics | $0.88 | $1.25 | 42.05% | Buy |
AUPH | Aurinia Pharmaceuticals | $9.55 | $13.00 | 36.13% | Buy |
MDGL | Madrigal Pharmaceuticals | $306.08 | $315.75 | 3.16% | Buy |
PTCT | PTC Therapeutics | $47.02 | $48.00 | 2.08% | Hold |
EXEL | Exelixis | $34.69 | $30.89 | -10.95% | Buy |
TGTX | TG Therapeutics | $33.57 | $23.75 | -29.25% | Buy |